A clinical trial of a new Ebola vaccine (ChAd3-EBO-Z) that resulted from an unprecedented global consortium assembled at the behest of the World Health Organization has found that it is well tolerated and stimulates strong immune responses in adults in Mali, West Africa and in the US, according to a study published today in the journal Lancet Infectious Disease. If the vaccine is ultimately found to be safe and effective, it could offer crucial protection for contacts (family members, neighbors, etc.) of patients with confirmed Ebola disease in future epidemics, thereby helping to interrupt transmission. Larger trials of the vaccine sponsored, by GSK Biologicals, have already begun.
The study, carried out in Mali, West Africa and Baltimore, included the first testing of this vaccine in adult health care workers and other at-risk persons in Africa. It identified the dose to be used in subsequent clinical trials and for large-scale manufacture of the vaccine. The researchers say that if larger trials (some already ongoing at CVD-Mali) corroborate the vaccine’s clinical acceptability and immunogenicity, and with evidence of protection from future field trials or from non-human primate challenge models, the vaccine could obtain regulatory approvals to become a tool to interrupt transmission in future outbreaks. This would be achieved by vaccinating all people who have come into contact with confirmed Ebola cases.
The investigators also found that the administration of a booster vaccination with another vector vaccine producing Ebola virus antigens led to further enhanced immune responses likely to be associated with long-lived protection. This “prime-boost” approach provides a way to vaccinate health care workers and other front-line workers who live in areas where Ebola poses a threat to re-emerge and who need prior enduring protection.
The trial was carried out by a group of faculty researchers within the Center for Vaccine Development (CVD) of the University of Maryland School of Medicine (UM SOM), led by Milagritos D. Tapia, MD and Kirsten Lyke, MD, collaborating closely with Professor Samba O. Sow, MD, MSc, Director General of the Center for Vaccine Development of Mali (CVD-Mali, an institution jointly maintained by the Ministry of Health of Mali and CVD-UM SOM).
Drs. Tapia and Lyke are also Associate Professors in the Department of Pediatrics and Medicine, respectively, at CVD-UM SOM., provided overall coordination of this study that evaluated the experimental Ebola vaccine (ChAd3-EBO-Z) developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and GlaxoSmithKline (GSK). Other key partners in the study included the University of Oxford’s Jenner Institute and the World Health Organization.
The study was the result of a consortium of the World Health Organization (WHO), the VRC, the Jenner Institute at the University of Oxford, CVD-Mali, CVD-UM SOM, and GSK Biologicals (manufacturer of the vaccine).
The study also involved others at CVD-UM SOM, including Marcelo B. Sztein, MD, and, James D. Campbell, MD, MS, both of whom are Professors of Pediatrics at UM SOM, as well as Rezwanul Wahid, PhD, Assistant Professor of Pediatrics at UM SOM.
“This is a crucial step on the road to using this vaccine in humans,” said Dr. Levine. “This gives us essential information that the vaccine is not only well-tolerated but the high dose stimulates strong immune responses in adults in West Africa, the global region where the Ebola outbreak was rampant last year.”
The Latest on: Ebola vaccine
via Google News
The Latest on: Ebola vaccine
- A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different cladeson January 10, 2020 at 4:08 am
We have previously developed a fast-acting and efficacious vaccine against Ebola virus (EBOV) using the vesicular stomatitis virus (VSV) platform. In this study, we generated recombinant VSV-based ...
- Here are some key people who made an Ebola vaccine happenon January 9, 2020 at 5:14 pm
Many people contributed to the development of Merck’s Ebola vaccine, the first licensed one for the disease based on data showing it works in humans. From the earliest work to turn a livestock virus ...
- The complex logistics of Ebola responseon January 9, 2020 at 1:53 am
Nearly half of the supplies were for infection and prevention control and laboratory work. The organization has to date also delivered more than 17 million gloves, over 2 million surgical masks, 909 ...
- Emergex Raises More Than US$11 Million in a Series A Round to Progress Its Pipeline of Set-Point Vaccines for Infectious Diseaseson January 9, 2020 at 12:00 am
Emergex develops set-point vaccines to prevent some of the world's most immediate and virulent diseases such as Zika, Dengue Fever, Ebola and pandemic Flu Vickers ...
- The WHO and FDA Approve Ebola Vaccine, Erveboon January 8, 2020 at 2:23 am
A new, injectable vaccine has been approved to fight the deadly and highly contagious virus, Ebola. Health officials hope it can start to mitigate current and future outbreaks of the disease. As of ...
- NYU Langone Health announces launch of a multidisciplinary Vaccine Centeron January 7, 2020 at 11:40 am
Vaccine research is of great importance to humankind. We still lack widely effective vaccines for many long-standing diseases like AIDS, TB, and malaria. In addition, new threats like Zika and Ebola ...
- Pharmalittle: The inside story of an Ebola vaccine; fewer adults received opioid prescriptionson January 7, 2020 at 6:33 am
Hello, everyone, and how are you today? We are doing just fine, thank you, as we ease back into a new year. The short person has returned to the local schoolhouse and the official mascot has resumed ...
- NYU Langone Health Launches Multi-Faceted Vaccine Centeron January 7, 2020 at 6:00 am
/PRNewswire/ -- Building on its illustrious landmark-achieving history in the field of immunology, NYU Langone Health announced today the launch of a ...
- An Ebola patient treated in the U.S. chose to remain anonymous. Now he's telling his story.on January 4, 2020 at 7:30 am
Years of disabling PTSD followed Preston Gorman's unlikely survival after he contracted the fearsome disease in Sierra Leone.
- Pig Ebola Might Make Tyson’s Stock Price Go Hog-Wildon January 3, 2020 at 8:12 am
Like Ebola, though, it's extremely contagious and spreads like wildfire among domestic ... Some analysts believe that China's pig stock won't recover to pre-ASFV levels until four to six years after ...
via Bing News